Free cookie consent management tool by TermsFeed Policy Generator

Ensayos Clínicos

Estudio de comparación de Daratumumab y Velcade (bortezomib) Melfalán-Prednisona (VMP) comparado con Velcade Melfalán-Prednisona (VMP) en participantes con mieloma múltiple no tratado previamente A Phase 3, Randomized, controlled, open-label study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Conbination with VMP (D VMP) in subjects with previously untreated multiple myeloma who are ineligibl for high-dose-therapy- ALCYONE

Ficha Técnica

Investigador Principal

MIGUEL ANGEL ALVAREZ RIVAS

Promotor

JANSSEN-CILAG INTERNATIONAL N.V.

ESTADO

CERRADO

DEPARTAMENTO

Hematología y Hemoterapia

Código EudraCT: 2014-002272-88

Número protocolo: 54767414MMY3007

Fecha Inicio: 2015-02-19

Fecha Fin: 2019-12-31